Arthneeti
All Q2 FY26 results →
P.

Pfizer Inc.

Q2 FY26Pharmaceuticals

Pfizer Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹26
Market cap₹1.5L Cr
P/E19.7
Updated29 May 2026
Read3 min read

Pfizer Inc. Q2 FY26 key numbers

Revenue
Launch and acquired products are already growing 22% operationally with $3.1 billion Q1 revenue and expected continued growth.

As stated in Pfizer Inc.'s Q2 FY26 earnings call transcript · published 29 May 2026. Reported figures, not investment advice.

The short version

- Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products. - Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by a strong pipeline and launched/acquired products.

From Pfizer Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products.
  • Growth momentum comes from oncology assets, obesity therapies, vaccines (RSV, pediatric, maternal immunization), and primary care franchises.
  • The obesity market, especially in China and emerging markets with high prevalence, is a significant growth driver.
  • Launch and acquired products are already growing 22% operationally with $3.1 billion Q1 revenue and expected continued growth.
  • Vaccines maintain strong market leadership with over 60% market share in key categories.
  • Despite near-term losses from expiring patents, new products and pipeline assets with multiple risk-adjusted readouts support long-term top-line growth.

2 more points from Pfizer Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Pfizer Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Pfizer continues to invest significantly in R&D, with $2.5 billion invested in internal R&D in Q1 2026, focusing on oncology, obesity, and other key therapeutic areas.
  • They are making targeted investments today to drive revenue growth later in the decade and beyond.
  • The company is investing in AI integration across R&D, commercial, manufacturing, and enterprise functions to accelerate innovation and improve decision-making.
  • Manufacturing optimization programs are ongoing, aiming for $700 million in savings in 2026, with $175 million realized in Q1.
  • Business development capacity stands at approximately $7 billion, primarily for pipeline support and opportunistic acquisitions.

2 more points from Pfizer Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Pfizer Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Pfizer Inc. said on order book & pipeline — free account, 30 seconds.

What the Q2 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

Continue your research

What Pfizer Inc.'s management said in earlier quarters

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Axsome Therapeutics, Inc. (Q2 FY26)

    Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Viatris Inc. (Q2 FY26)

    Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Pfizer Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Pfizer Inc. Q2 FY26 results?

- Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products. - Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by a strong pipeline and launched/acquired products.

What is Pfizer Inc. share price analysis?

Pfizer Inc. currently shows a below-average growth signal. The stock trades at a P/E of 19.7 with a market cap of $148,983. Investors should review the full earnings analysis for detailed insights.

Is Pfizer Inc. planning capital expenditure?

- Pfizer continues to invest significantly in R&D, with $2.5 billion invested in internal R&D in Q1 2026, focusing on oncology, obesity, and other key therapeutic areas.

Keep Pfizer Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.